Corcept Therapeutics Incorporated - Common Stock (CORT) stock analysis
CORT · Corcept Therapeutics Incorporated - Common Stock
Latest recorded price: USD 69.22
Model-estimated fair value: USD 19.41. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $69.22, CORT trades 256.7% above the model's base-case value of $19.41. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $15.44 in the conservative case and $24.18 in the optimistic case, with a valuation confidence score of 75/100. Fiscal 2025 figures: revenue growth 23.7%, free cash flow margin 18.6%, ROIC 12.8%. The model flags 1 risk signal for this company.
Similar companies in Healthcare
- CRISPR Therapeutics AG - Common Shares (CRSP)
- Cytokinetics, Incorporated (CYTK)
- Denali Therapeutics Inc. - Common Stock (DNLI)
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)
- Fortrea Holdings Inc. - Common Stock (FTRE)
- Halozyme Therapeutics, Inc. (HALO)
- Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)